Tearsheet

Agilon Health (AGL)


Market Price (12/20/2025): $0.7299 | Market Cap: $302.5 Mil
Sector: Health Care | Industry: Health Care Facilities

Agilon Health (AGL)


Market Price (12/20/2025): $0.7299
Market Cap: $302.5 Mil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -90%
Weak multi-year price returns
2Y Excs Rtn is -139%, 3Y Excs Rtn is -167%
Penny stock
Mkt Price is 0.7
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -76%
  Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -374 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.4%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more.
  Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -1.1%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.2%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.9%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -106%
5   High stock price volatility
Vol 12M is 103%
6   Key risks
AGL key risks include [1] an inability to accurately forecast and manage medical costs, Show more.
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -90%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -76%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -139%, 3Y Excs Rtn is -167%
4 Penny stock
Mkt Price is 0.7
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -374 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.4%
6 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -1.1%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.2%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.9%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -106%
9 High stock price volatility
Vol 12M is 103%
10 Key risks
AGL key risks include [1] an inability to accurately forecast and manage medical costs, Show more.

Valuation, Metrics & Events

AGL Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback

1. Disappointing Second Quarter 2025 Financial Results: Agilon Health reported second-quarter results that fell short of analyst expectations for revenue, medical margin, and EBITDA. The company experienced a gross loss of $52 million, a significant deterioration from the previous year's profit, and medical margin swung to a negative $53 million.

2. Withdrawal of Full-Year 2025 Guidance: The company suspended its previously issued full-year 2025 financial guidance. This action was attributed to ongoing leadership transition, shifts in market dynamics, and the rollout of new performance visibility tools, contributing to investor uncertainty.

3. Leadership Transition and Executive Turnover: CEO Steven Sell stepped down from his role as President, CEO, and Director. Co-founder and Chairman Ronald A. Williams was appointed Executive Chairman to lead an interim Office of the Chairman while the board searched for a permanent CEO replacement.

4. Higher-Than-Expected Medical Costs and Reduced Risk Adjustment Revenue: Agilon Health faced increased medical expenses, particularly from higher-than-expected specialist visits, Part B drugs, outpatient surgeries, and supplemental benefits. Additionally, the company projected significant shortfalls in risk adjustment revenue for both 2024 and 2025.

5. Analyst Downgrades and Revised Outlooks: Following the challenging financial results and outlook, several analysts significantly lowered their price targets and financial projections for Agilon Health, reflecting diminished confidence in the company's near-term performance. For instance, Barclays lowered its price target by 50% to $1.50 from $3.00.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
AGL Return-40%-22%-85%-63%
Peers Return-24%-7%-24%14%
S&P 500 Return16%27%-19%24%23%16%112%

Monthly Win Rates [3]
AGL Win Rate38%50%58%33%33% 
Peers Win Rate39%53%48%35%53% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
AGL Max Drawdown-44%-34%-87%-73% 
Peers Max Drawdown-50%-32%-45%-34% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: PRVA, ASTH, PIII, ALHC, INNV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/19/2025 (YTD)

How Low Can It Go

Unique KeyEventAGLS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-75.4%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven307.3%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days

Compare to


In The Past

Agilon Health's stock fell -75.4% during the 2022 Inflation Shock from a high on 6/18/2021. A -75.4% loss requires a 307.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Agilon Health (AGL)

Better Bets than Agilon Health (AGL)

Latest Trefis Analyses

Trade Ideas

Select past ideas related to AGL. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
17.4%17.4%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-6.7%-6.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
10.9%10.9%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.7%2.7%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
11.4%11.4%-5.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
17.4%17.4%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-6.7%-6.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
10.9%10.9%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.7%2.7%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
11.4%11.4%-5.1%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for Agilon Health

Peers to compare with:

Financials

AGLPRVAASTHPIIIALHCINNVMedian
NameAgilon H.Privia H.Astrana .P3 Healt.Alignmen.InnovAge  
Mkt Price0.7323.6423.874.1220.426.0013.21
Mkt Cap0.32.91.20.04.10.81.0
Rev LTM5,8862,0432,8961,4453,6378852,470
Op Inc LTM-3742861-2472-3-0
FCF LTM-11511197-1231513666
FCF 3Y Avg-1548593-95-30-9-19
CFO LTM-69111107-1231824475
CFO 3Y Avg-11685108-95624

Growth & Margins

AGLPRVAASTHPIIIALHCINNVMedian
NameAgilon H.Privia H.Astrana .P3 Healt.Alignmen.InnovAge  
Rev Chg LTM5.2%19.0%68.2%-2.1%47.4%12.5%15.7%
Rev Chg 3Y Avg42.2%17.4%41.6%15.8%38.8%8.4%28.1%
Rev Chg Q-1.1%32.5%99.7%-4.7%43.5%15.1%23.8%
QoQ Delta Rev Chg LTM-0.3%7.5%19.7%-1.2%9.0%3.6%5.6%
Op Mgn LTM-6.4%1.4%2.1%-17.1%0.1%-0.3%-0.1%
Op Mgn 3Y Avg-5.3%1.2%4.9%-16.3%-4.3%-2.9%-3.6%
QoQ Delta Op Mgn LTM0.0%0.3%-0.8%4.1%0.8%1.6%0.6%
CFO/Rev LTM-1.2%5.4%3.7%-8.5%5.0%5.0%4.3%
CFO/Rev 3Y Avg-2.5%4.7%6.2%-7.0%-0.7%-0.0%-0.4%
FCF/Rev LTM-1.9%5.4%3.3%-8.5%4.1%4.1%3.7%
FCF/Rev 3Y Avg-3.3%4.7%5.3%-7.0%-2.2%-1.6%-1.9%

Valuation

AGLPRVAASTHPIIIALHCINNVMedian
NameAgilon H.Privia H.Astrana .P3 Healt.Alignmen.InnovAge  
Mkt Cap0.32.91.20.04.10.81.0
P/S0.11.40.40.01.10.90.7
P/EBIT-1.0102.916.6-0.1-9,236.7-48.6-0.5
P/E-1.0159.8123.2-0.1-195.3-46.9-0.5
P/CFO-4.426.211.0-0.122.418.414.7
Total Yield-101.9%0.6%1.5%-973.3%-0.5%-2.1%-1.3%
Dividend Yield0.0%0.0%0.7%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-13.4%3.3%5.7%-2,907.2%-2.7%-0.9%-1.8%
D/E0.10.00.919.70.10.10.1
Net D/E-0.9-0.10.516.9-0.1-0.0-0.0

Returns

AGLPRVAASTHPIIIALHCINNVMedian
NameAgilon H.Privia H.Astrana .P3 Healt.Alignmen.InnovAge  
1M Rtn43.1%4.9%8.4%-32.7%25.0%19.3%13.8%
3M Rtn-36.7%5.7%-14.0%-50.0%23.5%29.6%-4.2%
6M Rtn-65.2%8.2%-0.5%-34.1%46.3%54.2%3.8%
12M Rtn-60.9%17.4%-32.0%-56.3%98.8%70.0%-7.3%
3Y Rtn-95.5%1.6%-17.3%-96.8%76.8%-9.6%-13.5%
1M Excs Rtn40.2%2.0%5.5%-35.6%22.2%16.4%10.9%
3M Excs Rtn-37.1%1.1%-14.0%-52.8%17.4%19.1%-6.4%
6M Excs Rtn-79.3%-4.0%-18.2%-46.7%32.7%37.7%-11.1%
12M Excs Rtn-76.2%0.8%-45.8%-70.6%75.6%34.1%-22.5%
3Y Excs Rtn-166.9%-77.4%-90.3%-168.8%0.2%-88.6%-89.5%

Financials

Segment Financials

Revenue by Segment

$ Mil2024202320222021
Medical services revenue4,3072,3851,8301,214
Other operating revenue9344
Total4,3162,3881,8341,218


Price Behavior

Short Interest

Short Interest: As Of Date11282025
Short Interest: Shares Quantity17,931,905
Short Interest: % Change Since 11152025-13.8%
Average Daily Volume12,856,772
Days-to-Cover Short Interest1.39
Basic Shares Quantity414,465,000
Short % of Basic Shares4.3%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20254.0%-14.6%-9.9%
5/6/2025-24.0%-39.5%-52.9%
2/25/2025-7.4%-12.7%24.5%
11/7/2024-34.1%-38.7%-19.7%
8/6/2024-9.3%-10.3%-34.4%
5/7/20244.2%10.4%36.5%
2/27/2024-1.9%-7.7%-11.6%
11/2/2023-13.2%-30.9%-32.9%
...
SUMMARY STATS   
# Positive875
# Negative8911
Median Positive4.1%8.3%24.5%
Median Negative-9.8%-12.7%-11.6%
Max Positive16.0%15.9%36.5%
Max Negative-34.1%-39.5%-52.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251104202510-Q 9/30/2025
6302025804202510-Q 6/30/2025
3312025506202510-Q 3/31/2025
12312024225202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024806202410-Q 6/30/2024
3312024507202410-Q 3/31/2024
12312023227202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023509202310-Q 3/31/2023
12312022301202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021303202210-K 12/31/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value
Value of
Held Shares
Form
0McLoughlin Karen 12132024Buy2.2025,00055,085161,214Form
1Battaglia Silvana12132024Buy2.0125,06250,269132,672Form
2MCKENZIE DIANA 12112024Buy2.2812,50028,474116,900Form
3Wulf John William 12112024Buy2.1845,00098,145449,576Form